C
C. Angel Cooper
Researcher at Pfizer
Publications - 6
Citations - 551
C. Angel Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Tigecycline & Glycylcycline. The author has an hindex of 5, co-authored 6 publications receiving 501 citations.
Papers
More filters
Journal ArticleDOI
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Antonio T. Freire,Vasyl Melnyk,Min Ja Kim,Oleksiy Datsenko,Oleksandr Dzyublik,Felix Glumcher,Yin Ching Chuang,Robert Maroko,Gary Dukart,C. Angel Cooper,Joan M. Korth-Bradley,Nathalie Dartois,Hassan Gandjini +12 more
TL;DR: Overall, the tigecycline regimen was noninferior to the imipenem/cilastatin regimen for the c-mITT but not the CE population; this difference appears to have been driven by results in VAP patients.
Journal ArticleDOI
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia
Cristina Tanaseanu,Carlos Bergallo,Osvaldo Teglia,Abel Jasovich,Maria Eugenia Oliva,Gary Dukart,Nathalie Dartois,C. Angel Cooper,Hassan Gandjini,Rajiv Mallick +9 more
TL;DR: Tigecycline appeared safe and achieved cure rates similar to LEV in hospitalized patients with CAP, and microbiologic efficacy and susceptibility to TGC for CAP bacteria were significantly higher in TGC than in LEV.
Journal ArticleDOI
Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline
Sujata M. Bhavnani,Christopher M. Rubino,Jeffrey P. Hammel,Alan Forrest,Nathalie Dartois,C. Angel Cooper,Joan M. Korth-Bradley,Paul G. Ambrose +7 more
TL;DR: The impact of pharmacological and patient-specific factors on the clinical and microbiological responses were demonstrated and the MIC had the greatest statistical significance.
Journal ArticleDOI
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
Cristina Tanaseanu,Slobodan Milutinovic,Petre I Calistru,Janos Strausz,Marius Zolubas,Valeriy Chernyak,Nathalie Dartois,Nathalie Castaing,Hassan Gandjini,C. Angel Cooper +9 more
TL;DR: It is suggested that IV tigecycline is non-inferior to IV levofloxacin and is generally well-tolerated in the treatment of hospitalized adults with CAP.
Journal ArticleDOI
Pharmacokinetics and Safety Profile of Tigecycline in Children Aged 8 to 11 Years With Selected Serious Infections: A Multicenter, Open-Label, Ascending-Dose Study
Jay Purdy,Sylvie Jouve,Jean Li Yan,Ivana Balter,Nathalie Dartois,C. Angel Cooper,Joan M. Korth-Bradley +6 more
TL;DR: A tigecycline dosage of ∼1.2 mg/kg q12h may represent the most appropriate dosage for subsequent evaluation in Phase III clinical trials in children aged 8 to 11 years with selected serious bacterial infections.